Pharmaceutical stocks hiding in the shadows
Investors' focus on shares of GLP-1 heavyweights has overshadowed the appeal of other drugmakers with a favorable valuation, a decent dividend and a healthy pipeline of products, according to Fidelity's John Sheehy.
- Within the dynamic, innovation-driven health care sector, the spotlight has recently been fixed on headline-grabbing developments in GLP-1 treatments for obesity and diabetes, says Fidelity Portfolio Manager John Sheehy, who believes the attention has resulted in overlooked potential among pharmaceutical companies he thinks can help deliver a steady diet of revenue and earnings growth.
- "Several of these unnoticed high-quality companies are trading at a valuation reminiscent of a decade ago, an era marked by considerable concern about patent cliffs and waning innovation," says Sheehy, who helms Fidelity Advisor® Equity Dividend Income Fund.
- The fund seeks a yield from dividend and interest income that exceeds the composite dividend yield on securities in the S&P 500® index. As manager, Sheehy emphasizes high-quality firms with either a favorable or improving return, as well as those with a strong balance sheet, including cash on hand or cash the enterprise is reasonably expected to generate in the near future.
- Accordingly, and based on Sheehy's aim to capitalize on the recent divergence among drugmakers, he has built an overweight allocation to the pharmaceuticals, biotechnology & life sciences industry, which represents more than 9% of the portfolio's assets as of April 30.
- "Within this group, I have seen great opportunities to add to fund positions in high-quality, dividend-paying stocks at a reasonable price, which is what the fund is all about," he says.
- He thinks three stocks in particular are well-positioned to potentially move the needle in the coming years, as they feature solid business fundamentals, promising drug pipelines, a history of returning value to shareholders, and the likelihood of achieving healthy revenue and earnings growth.
- Gilead Sciences, an outsized position in the fund, is channeling its expertise and legacy of innovation into a potentially promising new oncology business, according to Sheehy, who expects the effort could yield substantial growth and redefine the company's future.
- He also notes GSK, which, despite facing lower vaccine sales, has showcased profit growth, meaningful progress in research and development, advances in specialty medicines, and successful new product launches in oncology and HIV — a testament to the company's ability to adapt and thrive.
- Lastly, Sheehy favors Merck for its One Pipeline strategy, which blends internal innovation with external science through business development. "As one of the most active dealmakers in the industry, the company appears well-positioned to navigate the complexity of the pharmaceutical landscape with precision and foresight," he concludes.
Fidelity Advisor Equity Dividend Income Fund (FIAVX)
Seeks a yield from dividend and interest income which exceeds the composite dividend yield on securities comprising the S&P 500 Index. In addition, consistent with the primary objective of obtaining dividend and interest income, the fund will consider the potential for achieving capital appreciation.
Related insights
View all
For specific fund information such as standard performance and holdings, please go to the "Funds Managed" link on this page.
Investment decisions should be based on an individual’s own goals, time horizon, and tolerance for risk. Nothing in this content should be considered to be legal or tax advice, and you are encouraged to consult your own lawyer, accountant, or other advisor before making any financial decision. These materials are provided for informational purposes only and should not be used or construed as a recommendation of any security, sector, or investment strategy.
Fidelity does not provide legal or tax advice and the information provided herein is general in nature and should not be considered legal or tax advice. Consult with an attorney or a tax professional regarding your specific legal or tax situation.
Past performance and dividend rates are historical and do not guarantee future results.
Investing involves risk, including risk of loss.
Diversification does not ensure a profit or guarantee against loss.
Sector funds can be more volatile because of their narrow concentration in a specific industry. Growth stocks can perform differently from other types of stocks and the market as a whole and can be more volatile than other types of stocks. Value stocks can perform differently than other types of stocks and can continue to be undervalued by the market for long periods of time. • Stock markets, especially foreign markets, are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. • Foreign securities are subject to interest rate, currency exchange rate, economic, and political risks, all of which are magnified in emerging markets. • In general the bond market is volatile, and fixed income securities carry interest rate risk. (As interest rates rise, bond prices usually fall, and vice versa. This effect is usually more pronounced for longer-term securities.) Fixed income securities also carry inflation, credit, and default risks for both issuers and counterparties. • Lower-quality bonds can be more volatile and have greater risk of default than higher-quality bonds. • The municipal market is volatile and can be significantly affected by adverse tax, legislative, or political changes, and the financial condition of the issuers of municipal securities. • The securities of smaller, less well-known companies can be more volatile than those of larger companies. • The funds can invest in securities that may have a leveraging effect (such as derivatives and forward-settling securities) that may increase market exposure, magnify investment risks, and cause losses to be realized more quickly. • Leverage can magnify the impact of adverse issuer, political, regulatory, market, or economic developments on a company. In the event of bankruptcy, a company’s creditors take precedence over the company’s stockholders. Although the companies that the fund invests in may be highly leveraged, the fund itself does not use leverage as an investment strategy. Changes in real estate values or economic downturns can have a significant negative effect on issuers in the real estate industry. In the event of bankruptcy, a company’s creditors take precedence over the company’s stockholders. Third-party marks are the property of their respective owners; all other marks are the property of FMR LLC.